Plk1 Mouse mAb (3F8)
- Known as:
- Plk1 Mouse mAb (3F8)
- Catalog number:
- ASAKAM-CC105F
- Product Quantity:
- 200 µg
- Category:
- -
- Supplier:
- Other suppliers
- Gene target:
- Plk1 Mouse mAb (3F8)
Related genes to: Plk1 Mouse mAb (3F8)
- Gene:
- PLK1 NIH gene
- Name:
- polo like kinase 1
- Previous symbol:
- PLK
- Synonyms:
- -
- Chromosome:
- 16p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-25
- Date modifiied:
- 2016-10-05
Related products to: Plk1 Mouse mAb (3F8)
Related articles to: Plk1 Mouse mAb (3F8)
- Lung cancer remains the leading cause of cancer-related mortality worldwide and is characterized by high aggressiveness and therapeutic resistance, partly driven by mitotic dysregulation. Key mitotic regulators, including kinases such as PLK1, AURKA, AURKB, and MPS1 and kinesins such as CENPE and Eg5, are frequently overexpressed in NSCLC and SCLC, contributing to chromosomal instability, aneuploidy, and highly proliferative tumor phenotypes. Although multiple inhibitors targeting these proteins have been developed, their clinical efficacy as monotherapies has been limited. This is largely due to insufficient target dependency, adaptive resistance mechanisms, mitotic slippage, activation of compensatory pathways, and dose-limiting toxicity. This review integrates current knowledge on the physiological roles of major mitotic regulators, their dysregulation in lung tumorigenesis, and the biological and pharmacological barriers that underlie the limited success of antimitotic drugs. We further highlight preclinical and clinical evidence supporting rational combination strategies designed to enhance the antitumor activity of mitotic inhibitors while minimizing toxicity. Together, these insights underscore the need for refined therapeutic approaches that better exploit vulnerabilities in mitotic control to improve outcomes for patients with lung cancer. - Source: PubMed
Publication date: 2026/03/24
Pinto BárbaraSilva João P NSilva Patrícia M ASarmento BrunoCarvalho-Tavares JulianaBousbaa Hassan - Polo-like kinase 1 (PLK1) is a master regulator of mitosis and a well-established driver of cancer progression. Strategies to target PLK1 have largely focused on RNA interference using small interfering RNAs or small-molecule inhibitors. Here, we introduce the direct intracellular targeting of the PLK1 interdomain linking the polo-box domain to the kinase domain using monoclonal antibodies. Three monoclonal antibodies recognizing the interdomain region were delivered into the cytosol of HeLa cells by electroporation. These antibodies were shown to bind PLK1 in living cells and to modulate mechanisms involved in mitotic progression. Our results establish these antibodies as tools to probe PLK1 function through real-time labeling and interference with the mitotic machinery. - Source: PubMed
Steyer ClémentAmé Jean-ChristopheDonzeau MarielShen KarieChiper ManuelaZuber Guy - Lung cancer remains a major global public health challenge, with lung adenocarcinoma being the most prevalent histologic subtype. Rosuvastatin, a widely used lipid-lowering agent, has recently attracted attention for its potential antitumor properties. This study investigates the underlying mechanisms and therapeutic potential of rosuvastatin in lung cancer. - Source: PubMed
Yin JieZhu JianjieGong YinhuaWu WentingZhang XinyuLi ChangYang YangChen YiliLi JianjunGu LeiHuang Jian-AnLiu ZeyiShen DanZeng Yuanyuan - Colorectal cancer (CRC) exhibits extensive cellular heterogeneity and complex tumor microenvironment (TME) interactions, which influence tumor progression and treatment response. However, the precise interplay between epithelial cells and cancer-associated fibroblasts and its prognostic relevance remain incompletely understood. - Source: PubMed
Publication date: 2026/04/27
Wu ShuoZhang GuancongYang JiajinWang Shuo - To explore the role of miR-593-5p targeting Polo-like kinase 1 (PLK1) in regulating biological behaviors of human gastric cancer (GC) cells. - Source: PubMed
Dong BaolongPeng JiangshanLi JinruMeng YunYang Xiaojun